Microbiotica is a leading, clinical stage biopharmaceutical company specialising in the development of precision live biotherapeutic products (LBPs) with lead products in immuno-oncology and inflammatory bowel disease.
Clinic-led microbiome discovery
At Microbiotica we have a purpose-built powerful, proprietary microbiome profiling platform to support drug discovery based on clinical data. This enables us to precisely identify specific bacterial strains associated with clinical benefit in specific patient populations.
Clinical stage programmes
Our microbiome platform is creating an innovative pipeline of products in immuno-oncology and inflammatory bowel disease, with two lead LBP candidates:
MB097
Co-therapy designed to enhance the efficacy and potency of immune checkpoint inhibitors (IPIs) in melanoma patients.
MELODY-1 is a UK/EU Phase 1b study to investigate the safety, tolerability, and initial signals of efficacy a once daily oral dose of MB097 for advanced melanoma, in combination with KEYTRUDA® (pembrolizumab), MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, in patients with cutaneous melanoma who have failed to respond to immunotherapies.
MB310
Monotherapy for ulcerative colitis (UC).
COMPOSER is a UK/EU Phase 1b study to investigate the safety and initial signals of efficacy of a once daily oral dose of MB310 as a monotherapy for the treatment of ulcerative colitis, an inflammatory bowel disease.
Expertise driving our precision capabilities
The Microbiotica team has significant expertise in microbiology, bioinformatics, translational biology and LBP manufacturing and development.
History
Microbiotica was established as a spin-out of our co-founder Dr Trevor Lawley’s laboratory at the Wellcome Sanger Institute, the world leading genomics centre founded to deliver the Human Genome Project. Trevor’s scientific team addressed key barriers to translating microbiome science into therapeutics by pioneering the anaerobic culturing and banking of the human gut microbiota and developing innovative analytical approaches for precise microbiome profiling.
Microbiotica has built on this foundation to scale-up its core capabilities and technologies creating a cutting-edge platform for the discovery and development of LBPs. We aim to deliver safe and precise microbiome medicines to provide benefit for patients.
The company has raised £62M equity investment to date, including a £50M Series B in 2022. It occupies purpose-designed facilities based at the Chesterford Research Park, Cambridge, UK.
